JP2018048151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018048151A5 JP2018048151A5 JP2017192907A JP2017192907A JP2018048151A5 JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5 JP 2017192907 A JP2017192907 A JP 2017192907A JP 2017192907 A JP2017192907 A JP 2017192907A JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer stem
- brain tumor
- pharmaceutical composition
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10185930.4 | 2010-10-01 | ||
| EP10185930A EP2446895A1 (en) | 2010-10-01 | 2010-10-01 | EPH receptor expression in tumor stem cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200808A Division JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Division JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018048151A JP2018048151A (ja) | 2018-03-29 |
| JP2018048151A5 true JP2018048151A5 (enExample) | 2018-05-17 |
| JP6618968B2 JP6618968B2 (ja) | 2019-12-11 |
Family
ID=43856109
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2017192907A Active JP6618968B2 (ja) | 2010-10-01 | 2017-10-02 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9078857B2 (enExample) |
| EP (2) | EP2446895A1 (enExample) |
| JP (4) | JP2013540117A (enExample) |
| KR (2) | KR20130095286A (enExample) |
| AU (1) | AU2011310109B2 (enExample) |
| CA (1) | CA2813101C (enExample) |
| DK (1) | DK2621513T3 (enExample) |
| ES (1) | ES2616444T3 (enExample) |
| NZ (1) | NZ609594A (enExample) |
| PL (1) | PL2621513T3 (enExample) |
| WO (1) | WO2012042021A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ611428A (en) | 2010-12-08 | 2015-07-31 | Stemcentrx Inc | Novel modulators and methods of use |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2733206A1 (en) * | 2012-11-19 | 2014-05-21 | Naroa LLC | Method for the isolation for mammalian stem cells using EphA2 and uses thereof |
| JP2016540826A (ja) | 2013-11-04 | 2016-12-28 | ファイザー・インク | 抗ｅｆｎａ４抗体−薬物コンジュゲート |
| RU2708075C2 (ru) | 2014-04-30 | 2019-12-04 | Пфайзер Инк. | Конъюгаты анти-ртк7 антитело-лекарственное средство |
| WO2016092378A1 (en) * | 2014-12-10 | 2016-06-16 | Angelo Luigi Vescovi | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors |
| KR20180016391A (ko) | 2015-05-08 | 2018-02-14 | 플로우조, 엘엘시 | 데이터 발견 노드 |
| US11174484B2 (en) | 2015-11-10 | 2021-11-16 | B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
| EP4129311A4 (en) * | 2020-03-31 | 2024-06-12 | Keio University | Therapeutic agent using genome-edited pluripotent stem cell |
| WO2026022122A1 (en) * | 2024-07-23 | 2026-01-29 | Eos Research Sa | Checkpoint inhibitors in the treatment of glioblastoma multiforme |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682173A4 (en) * | 2003-10-15 | 2007-10-31 | Medimmune Inc | EPHA2 VACCINE ON LISTERIA BASE |
| EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US8343461B2 (en) * | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| BRPI0816094A2 (pt) * | 2007-08-30 | 2015-03-03 | Daiichi Sankyo Co Ltd | Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo. |
-
2010
- 2010-10-01 EP EP10185930A patent/EP2446895A1/en not_active Withdrawn
-
2011
- 2011-04-18 US US13/089,217 patent/US9078857B2/en active Active
- 2011-09-30 EP EP11778540.2A patent/EP2621513B1/en active Active
- 2011-09-30 PL PL11778540T patent/PL2621513T3/pl unknown
- 2011-09-30 ES ES11778540.2T patent/ES2616444T3/es active Active
- 2011-09-30 WO PCT/EP2011/067114 patent/WO2012042021A1/en not_active Ceased
- 2011-09-30 KR KR1020137011310A patent/KR20130095286A/ko not_active Ceased
- 2011-09-30 AU AU2011310109A patent/AU2011310109B2/en active Active
- 2011-09-30 DK DK11778540.2T patent/DK2621513T3/en active
- 2011-09-30 NZ NZ609594A patent/NZ609594A/en unknown
- 2011-09-30 KR KR1020167002577A patent/KR101719966B1/ko active Active
- 2011-09-30 JP JP2013530753A patent/JP2013540117A/ja active Pending
- 2011-09-30 CA CA2813101A patent/CA2813101C/en active Active
-
2015
- 2015-10-09 JP JP2015200808A patent/JP6523910B2/ja active Active
-
2017
- 2017-10-02 JP JP2017192907A patent/JP6618968B2/ja active Active
-
2019
- 2019-11-13 JP JP2019205190A patent/JP2020037579A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018048151A5 (enExample) | ||
| JP5902138B2 (ja) | 癌治療と幹細胞調節のための方法 | |
| MX2024010140A (es) | Nuevos metodos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| AR060150A1 (es) | Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular | |
| CY1122575T1 (el) | Φαρμακοτεχνικες μορφες διστρωματικου δισκιου | |
| JP2015520753A5 (enExample) | ||
| JP2019516754A5 (enExample) | ||
| JP2016501013A5 (enExample) | ||
| JP2007526248A5 (enExample) | ||
| WO2007055941A3 (en) | Histone deacetylase inhibitors with aryl-pyrazolyl motifs | |
| TR201900057T4 (tr) | Selektif histon deasetilaz (HDAC) inhibitörleri olarak yeni azaindol deriveleri ve bunları içeren farmasötik bileşimler. | |
| JP2015514778A5 (enExample) | ||
| WO2016145234A3 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2013511560A5 (enExample) | ||
| JP2018023397A5 (enExample) | ||
| Wang et al. | Gene therapy for vein graft failure | |
| JP2017516832A5 (enExample) | ||
| Zhang et al. | The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance | |
| JP2015512447A5 (enExample) | ||
| Shahi | Role of the Shh Signaling Pathway in the Most Common Brain Tumor “Glioma” role in Glioma Growth | |
| ABOUSHADY et al. | Correlation between Decreased Nuclear Factor Kappa Beta (NFKβ), Kras, and Braf Genes' Expression and Enhanced Chemosensitivity of Human Squamous Cell Carcinoma Cells to 5-fluorouracil and/or Mesenchymal Stem Cells-derived Microvesicles. | |
| CN105232561B (zh) | 22(r)-羟基胆固醇作为parp1抑制剂的应用 |